Theralase Technologies Inc (TLTFF)

[123414]

Theralase Research Demonstrates Lead Drug Also Effective for Muscle Invasive Bladder Cancer (MIBC)


Toronto, Ontario – September 9, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that its latest research demonstrates that its lead Photo Dynamic Compound (“PDC”), TLD-1433, in addition to being indicated for the treatment of Non-Muscle Invasive Bladder Cancer (“NMIBC”), may also be effective for the treatment of Muscle Invasive Bladder Cancer (“MIBC”).
The latest research involved testing the Photo Dynamic Therapy (“PDT”) of TLD-1433 in an orthotopic rat bladder tumour model.
Procedure:
– 5 million AY27 rat bladder cancer cells per milliliter were instilled in the sensitized rat bladder for one hour to allow the cancer cells to attach.
– Tumours required two to three weeks to grow to an appropriate size
– TLD-1433 was intravesically infused into the rat’s bladder at either 0.6 mgmL-1 (representative of human low dose) or 6.0 mgmL-1 (representative of human high dose)
– After one hour incubation, TLD-1433 was removed and the bladder was washed three times with sterile water to remove any unabsorbed TLD-1433 mirroring the proposed human clinical treatment
– An optical fiber was inserted into the center of the rat bladder to deliver 1 hour green laser light for PDT, at a dose of 90 Jcm-2 again mirroring the human treatment
– Experiments were performed with drug only and light only controls to exclude any possibility that drug or light alone led to cell kill
– The rats were sacrificed two days post-PDT and their bladders were sent to the histopathology lab for analysis
 
Results (Representative of Human Low Dose):
– Five tumours treated with 0.6 mgmL-1 TLD-1433 (representative of human low dose) followed by PDT showed a strong response to the PDT with complete destruction of the tumour, with large areas of hemorrhage, necrosis (cell kill), and inflammation present throughout the whole depth of the tumour.
– Blood vessels of the submucosa, the muscle layer, and urothelium distal from the tumour area were unaffected by the PDT.
– Drug or light only controls showed no effect on the destruction of the tumour.

Two days after PDT treatment, the tumour mass shows widespread hemorrhage and inflammation, with an absence of cancer cells. The dark spots in the treated tumours are neutrophils responding to the widespread cell death and inflammation. Full thickness sectioning shows a completely necrotic (cell kill) tumour. The urothelium and the deeper muscle layers adjacent to the tumour are intact.


Read more at http://www.stockhouse.com/companies/bullboard?symbol=v.tlt&postid=25895911#21oeq4Iy1SZ8dQhp.99